Biogen marketing interviews focus on developing the disease awareness and market development programs for LEQEMBI that must simultaneously educate primary care physicians who see early Alzheimer's patients about the importance of referral to specialty neurology for amyloid evaluation, build neurologist confidence in LEQEMBI's clinical evidence and safety profile, and create the patient and caregiver awareness of Alzheimer's disease-modifying treatment options that drives the patient identification and diagnosis-seeking behavior that is the ultimate constraint on LEQEMBI's commercial uptake, managing the competitive position of Biogen's MS portfolio including TYSABRI and VUMERITY against Roche's Ocrevus, Novartis's Kesimpta, and Bristol Myers Squibb's Zeposia in the relapsing MS market where neurologist prescribing decisions are based on efficacy, safety, administration convenience, and the totality of the product profile that determines how each therapy fits into the neurologist's treatment algorithm, developing the Friedreich's ataxia market for SKYCLARYS as the first approved disease-modifying therapy in a rare neurological disease where patient advocacy communities, specialist neuromuscular disease physicians, and genetic testing programs are the primary channels for reaching the eligible patient population, and building the medical education and thought leadership programs that establish Biogen's scientific credibility in neurodegeneration as the foundation for LEQEMBI's clinical adoption and the company's emerging Alzheimer's and neurodegeneration research portfolio. The interview tests whether you understand how marketing at a neurology biotech differs from marketing at a diversified pharmaceutical company, an oncology biotech, or a medical device organization.

Start your free Biogen Marketing practice session.

What interviewers actually evaluate

Alzheimer's Disease Awareness and LEQEMBI Market Development, MS Portfolio Competitive Positioning, Rare Disease Friedreich's Ataxia Market Development, and Neuroscience Medical Education

Biogen marketing interviews probe whether you understand the disease awareness market development, multi-tier physician education, and patient advocacy engagement requirements that define marketing in neurology where the path from undiagnosed patient to treated patient involves multiple healthcare provider touchpoints and diagnostic steps that marketing must address at each stage. LEQEMBI market development requires understanding the dual challenge of increasing Alzheimer's disease identification and referral to specialty neurology while simultaneously building neurologist confidence in LEQEMBI's appropriate use and patient selection criteria. MS portfolio marketing requires understanding the differentiated positioning of TYSABRI and VUMERITY in the MS treatment algorithm.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
LEQEMBI Alzheimer's disease awareness and primary care physician education Do you understand how Biogen develops the disease awareness and referral education programs that address the primary care physician's role in recognizing early Alzheimer's disease symptoms and facilitating the diagnostic pathway that leads to amyloid evaluation and LEQEMBI treatment consideration, including how you reach primary care physicians with Alzheimer's recognition and referral messaging at a scale sufficient to meaningfully increase the rate of appropriate referrals to neurologists? Describe how you would develop Biogen's primary care physician education campaign for Alzheimer's disease recognition and specialist referral, targeting the estimated 250,000 primary care physicians who represent the first point of contact for the majority of early Alzheimer's patients, including how you identify the educational content gaps and practice barriers that prevent primary care physicians from consistently recognizing early Alzheimer's symptoms and making timely neurology referrals, how you develop the campaign content and channel strategy that reaches primary care physicians with Alzheimer's recognition guidance at scale given the resource constraints of a specialty neurology company whose sales force is not configured to detail primary care physicians, how you develop the digital and peer-to-peer channel strategy including CME programs, professional society partnerships, and primary care journal communications that reach the breadth of the primary care audience without a dedicated primary care sales force, and how you measure the campaign's effectiveness through leading indicators like referral volume to neurology and Alzheimer's evaluation rates rather than lagging LEQEMBI prescription volume
MS franchise competitive positioning and TYSABRI differentiation marketing Can you describe how Biogen develops the competitive marketing positioning for TYSABRI against Roche's Ocrevus in the relapsing MS market, where both therapies are high-efficacy IV infusion treatments competing for the subset of MS patients whose neurologist believes the magnitude of efficacy justifies the administration burden and safety monitoring requirements of an infused therapy? Walk through how you would develop Biogen's TYSABRI competitive positioning strategy for the active relapsing MS patient population where Ocrevus has been growing market share by offering annual infusion dosing versus TYSABRI's monthly infusion frequency, including how you develop the head-to-head clinical profile comparison that presents TYSABRI's superior efficacy in preventing relapses and disability progression in JC antibody negative patients relative to Ocrevus's efficacy profile, how you develop the JC negative patient identification and segmentation approach that focuses TYSABRI's positioning on the patient population where the therapy can be used without the PML risk monitoring that creates TYSABRI's primary competitive disadvantage versus Ocrevus, how you address the dosing convenience disadvantage of monthly TYSABRI infusions versus Ocrevus's annual dosing through the TOUCH program's established patient monitoring and infusion site network that provides continuity of care infrastructure, and how you develop the neurologist messaging framework that positions TYSABRI as the efficacy-first choice for JC negative patients with active relapsing MS who prioritize maximum relapse prevention
SKYCLARYS Friedreich's ataxia rare disease marketing and patient community development Do you understand how Biogen develops the marketing and patient community engagement programs for SKYCLARYS in the Friedreich's ataxia rare disease market, including how you reach the small, dispersed patient population through the neuromuscular disease specialist physicians, patient advocacy organizations, and genetic testing programs that are the primary channels for identifying and engaging eligible FA patients? Explain how you would develop the SKYCLARYS marketing and patient community program for Friedreich's ataxia, including how you build the specialist physician education program for the neuromuscular disease neurologists and movement disorder specialists who manage FA patients and who are the primary prescribers of disease-modifying therapy in this rare disease, how you develop the partnership with the Friedreich's Ataxia Research Alliance and other FA patient advocacy organizations that are central to the FA patient and caregiver community and that influence treatment decisions and clinical trial participation, what the genetic testing and disease awareness program looks like for improving FA diagnosis rates given that FA is underdiagnosed and that many patients receive ataxia diagnoses without the frataxin gene mutation testing that confirms FA diagnosis and SKYCLARYS eligibility, and how you measure SKYCLARYS commercial performance in a rare disease market where patient numbers are small and individual prescription decisions are highly visible
Biogen neurodegeneration medical education and scientific thought leadership Can you describe how Biogen develops the medical education and scientific thought leadership programs that build the neurologist and neuroscientist community's confidence in Biogen's neurodegeneration science and clinical development capabilities, including how you develop the scientific publication strategy, medical conference presence, and physician advisory board program that position Biogen as a trusted scientific partner in Alzheimer's disease and other neurological disease areas? Describe how you would develop Biogen's medical education and thought leadership program for Alzheimer's disease that builds neurologist and Alzheimer's specialist confidence in LEQEMBI's clinical evidence and appropriate patient selection, including how you develop the scientific publication strategy for the CLARITY AD Phase 3 trial data and the post-marketing patient registry data that provides real-world evidence of LEQEMBI's clinical impact in the broader treated population beyond the clinical trial setting, how you develop the medical conference presence at the Alzheimer's Association International Conference and American Academy of Neurology that presents LEQEMBI's clinical evidence in a format that supports informed prescribing decisions, what the medical advisory board program looks like for LEQEMBI and how you select and engage the Alzheimer's disease thought leaders who can provide clinical guidance on appropriate use and patient selection that reflects real-world prescribing considerations, and how you manage the scientific communication program in a way that is compliant with FDA's promotional regulations while providing neurologists with the clinical evidence and practical guidance they need to confidently prescribe LEQEMBI

How a session works

Step 1: Choose a Biogen marketing scenario: LEQEMBI primary care physician Alzheimer's recognition and referral campaign at scale without a dedicated primary care sales force, TYSABRI competitive positioning against Ocrevus in the JC antibody negative active relapsing MS patient population, SKYCLARYS Friedreich's ataxia rare disease physician education and patient community program, or Biogen Alzheimer's disease medical education and CLARITY AD data publication strategy.

Step 2: The AI interviewer asks realistic neurology biotech marketing questions: how you would develop the digital and CME channel strategy to reach primary care physicians at scale with Alzheimer's referral education, how you would develop the JC negative patient segmentation messaging for TYSABRI versus Ocrevus, or how you would structure the Friedreich's Ataxia Research Alliance partnership for SKYCLARYS patient community engagement.

Step 3: You respond as you would in the actual interview. The system scores your answer on audience segmentation specificity, competitive positioning depth, and rare disease market development quality.

Step 4: You get sentence-level feedback on what demonstrated genuine neurology biotech marketing expertise and what needs stronger Alzheimer's market development knowledge or MS competitive positioning specificity.

Frequently Asked Questions

Why is disease awareness marketing so important for LEQEMBI's commercial success?
LEQEMBI's commercial success depends on a diagnostic pipeline that begins with early Alzheimer's patients being recognized and evaluated by physicians before their disease has progressed beyond the mild cognitive impairment or mild dementia stages where LEQEMBI has demonstrated clinical benefit. The majority of Alzheimer's patients are not currently diagnosed at the early stages where LEQEMBI would be appropriate, and many of those who do receive a diagnosis do not follow through with the amyloid confirmation testing that is required for LEQEMBI prescribing. Disease awareness marketing that reaches both patients and their families with information about early Alzheimer's symptoms and the importance of early evaluation, and primary care physician education that improves recognition of early Alzheimer's symptoms and the likelihood of appropriate neurology referral, are the upstream market development activities that create the patient pipeline on which LEQEMBI's commercial growth depends.

How does Biogen position TYSABRI in the evolving MS treatment landscape?
TYSABRI occupies a high-efficacy position in the MS treatment algorithm as one of the few therapies with demonstrated superiority to interferon and glatiramer acetate-class therapies in head-to-head comparisons, making it a compelling option for patients with active relapsing MS where the neurologist believes the magnitude of efficacy justifies the monthly infusion requirement and the PML monitoring obligations. TYSABRI's primary competitive disadvantage is the PML risk in JC antibody positive patients, which has led some neurologists to transition high-risk TYSABRI patients to Roche's Ocrevus or Novartis's Kesimpta as these therapies have established their high-efficacy profiles without the same PML risk. Biogen's TYSABRI marketing focuses on the JC antibody negative patient population where TYSABRI can be used with the highest benefit-risk profile, and on the established neurologist-patient relationships and TOUCH program monitoring infrastructure that provide continuity of care advantages for long-term TYSABRI users.

What makes Friedreich's ataxia marketing uniquely challenging?
Friedreich's ataxia marketing presents unique challenges because the disease is rare, with an estimated 5,000 to 6,000 US patients, and many patients go undiagnosed or receive an ataxia diagnosis without the frataxin gene mutation testing that confirms Friedreich's ataxia specifically. The small patient population is scattered across the country and primarily managed by a limited number of neuromuscular disease specialists who have Friedreich's ataxia expertise, making the physician education program tractable but requiring the identification of all relevant treating physicians rather than relying on the broad-coverage sales force models used for more prevalent neurology conditions. Patient advocacy organizations, particularly the Friedreich's Ataxia Research Alliance, play an unusually large role in the rare disease ecosystem by connecting patients with specialist physicians, clinical research opportunities, and treatment information, making partnership with the FA advocacy community a central element of SKYCLARYS's commercial strategy.

How does FDA's pharmaceutical promotion regulation affect Biogen's marketing?
FDA regulates Biogen's promotional activities for its approved products under the Federal Food, Drug, and Cosmetic Act and its implementing regulations, which prohibit promotional claims that are false or misleading, require fair balance between benefit and risk information in promotional materials, and prohibit promoting products for uses that are not included in the approved labeling. For LEQEMBI, this means that Biogen's promotional materials must accurately represent the CLARITY AD clinical trial results and LEQEMBI's approved indication for early Alzheimer's, and must include fair balance disclosure of ARIA risks and the contraindication for patients who are ApoE4 homozygotes who were excluded from the CLARITY AD trial. Biogen's marketing and legal teams collaborate on the medical-legal review process for all promotional materials to ensure compliance with FDA's promotional regulations before the materials are distributed to neurologists or patients.

How does Biogen engage the Alzheimer's patient and caregiver community in its marketing?
Biogen's Alzheimer's disease marketing recognizes that the caregiver partner, typically a spouse or adult child of the person with Alzheimer's, is often the primary driver of the diagnostic and treatment-seeking process because early Alzheimer's patients may lack the insight to recognize their own cognitive symptoms or may minimize them out of denial or fear. Marketing programs that reach caregivers through the Alzheimer's Association, caregiver support groups, and digital communities where caregivers share information and seek guidance are important components of the market development strategy because caregivers who are aware of disease-modifying treatment options are more likely to pursue the specialist evaluation and amyloid testing that lead to LEQEMBI candidacy assessment. Biogen's direct-to-consumer marketing for LEQEMBI must comply with FDA's prescription drug advertising requirements, which require balanced fair disclosure of LEQEMBI's ARIA risks alongside the therapy's potential benefits.

Also practice

One full session free. No account required. Real, specific feedback.